Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
Latest Information Update: 06 Mar 2020
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms PASSRRA
- Sponsors Hikma Pharmaceuticals
- 03 Mar 2020 Status changed from recruiting to completed.
- 22 Nov 2017 New trial record